Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?

Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?

Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association